ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection Aug 4, 2020 by ReViral Ltd Read More
ReViral’s Phase 2a RSV Study publication selected as Editor’s Pick in February 2020 issue of ASM’s Antimicrobial Agents and Chemotherapy Jan 27, 2020 by ReViral Ltd Read More
ReViral Appoints Lawrence Blatt and Richard N. Kender to its Board of Directors Nov 27, 2019 by ReViral Ltd Read More
